FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2917909827> ?p ?o ?g. }

• W2917909827 endingPage "74" @default.
• W2917909827 startingPage "64" @default.
• W2917909827 abstract "The goal of this article is to provide recommendations about the management of muscle-invasive (MIBC) and metastatic bladder cancer. New molecular subtypes of MIBC are associated with specific clinical–pathological characteristics. Radical cystectomy and lymph node dissection are the gold standard for treatment and neoadjuvant chemotherapy with a cisplatin-based combination should be recommended in fit patients. The role of adjuvant chemotherapy in MIBC remains controversial; its use must be considered in patients with high-risk who are able to tolerate a cisplatin-based regimen, and have not received neoadjuvant chemotherapy. Bladder-preserving approaches are reasonable alternatives to cystectomy in selected patients for whom cystectomy is not contemplated either for clinical or personal reasons. Cisplatin-based combination chemotherapy is the standard first-line protocol for metastatic disease. In the case of unfit patients, carboplatin–gemcitabine should be considered the preferred first-line chemotherapy treatment option, while pembrolizumab and atezolizumab can be contemplated for individuals with high PD-L1 expression. In cases of progression after platinum-based therapy, PD-1/PD-L1 inhibitors are standard alternatives. Vinflunine is another option when anti-PD-1/PD-L1 therapy is not possible. There are no data from randomized clinical trials regarding moving on to immuno-oncology agents." @default.
• W2917909827 created "2019-03-02" @default.
• W2917909827 creator A5011923508 @default.
• W2917909827 creator A5017439917 @default.
• W2917909827 creator A5026620381 @default.
• W2917909827 creator A5038937574 @default.
• W2917909827 creator A5054850662 @default.
• W2917909827 creator A5056893451 @default.
• W2917909827 creator A5057408102 @default.
• W2917909827 creator A5068543301 @default.
• W2917909827 creator A5086554040 @default.
• W2917909827 creator A5089624043 @default.
• W2917909827 date "2018-12-18" @default.
• W2917909827 modified "2023-10-18" @default.
• W2917909827 title "SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018)" @default.
• W2917909827 cites W1752338025 @default.
• W2917909827 cites W1814430027 @default.
• W2917909827 cites W1845099892 @default.
• W2917909827 cites W1857682357 @default.
• W2917909827 cites W1893740135 @default.
• W2917909827 cites W1932620090 @default.
• W2917909827 cites W1952252771 @default.
• W2917909827 cites W1974722941 @default.
• W2917909827 cites W1975918912 @default.
• W2917909827 cites W1986438764 @default.
• W2917909827 cites W1995746323 @default.
• W2917909827 cites W2003665515 @default.
• W2917909827 cites W2009720434 @default.
• W2917909827 cites W2011458181 @default.
• W2917909827 cites W2027649047 @default.
• W2917909827 cites W2033775272 @default.
• W2917909827 cites W2044702943 @default.
• W2917909827 cites W2046937758 @default.
• W2917909827 cites W2054195724 @default.
• W2917909827 cites W2065741451 @default.
• W2917909827 cites W2067964015 @default.
• W2917909827 cites W2072065123 @default.
• W2917909827 cites W2097255042 @default.
• W2917909827 cites W2098028863 @default.
• W2917909827 cites W2102116016 @default.
• W2917909827 cites W2103257412 @default.
• W2917909827 cites W2103561213 @default.
• W2917909827 cites W2103725052 @default.
• W2917909827 cites W2105737543 @default.
• W2917909827 cites W2107575831 @default.
• W2917909827 cites W2113156769 @default.
• W2917909827 cites W2113235293 @default.
• W2917909827 cites W2118328604 @default.
• W2917909827 cites W2132379894 @default.
• W2917909827 cites W2137616140 @default.
• W2917909827 cites W2148562299 @default.
• W2917909827 cites W2151488185 @default.
• W2917909827 cites W2158276831 @default.
• W2917909827 cites W2160107406 @default.
• W2917909827 cites W2160866940 @default.
• W2917909827 cites W2164361265 @default.
• W2917909827 cites W2164791945 @default.
• W2917909827 cites W2166453367 @default.
• W2917909827 cites W2168846224 @default.
• W2917909827 cites W2169709372 @default.
• W2917909827 cites W2259802687 @default.
• W2917909827 cites W2270022169 @default.
• W2917909827 cites W2289712604 @default.
• W2917909827 cites W2329076941 @default.
• W2917909827 cites W2539843209 @default.
• W2917909827 cites W2558956747 @default.
• W2917909827 cites W2559804019 @default.
• W2917909827 cites W2566236100 @default.
• W2917909827 cites W2579143428 @default.
• W2917909827 cites W2582671354 @default.
• W2917909827 cites W2588916311 @default.
• W2917909827 cites W2755210674 @default.
• W2917909827 cites W2755607580 @default.
• W2917909827 cites W2760661635 @default.
• W2917909827 cites W2763670669 @default.
• W2917909827 cites W2777192533 @default.
• W2917909827 cites W2782762180 @default.
• W2917909827 cites W2889646458 @default.
• W2917909827 cites W2891320729 @default.
• W2917909827 cites W2891866600 @default.
• W2917909827 doi "https://doi.org/10.1007/s12094-018-02001-x" @default.
• W2917909827 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6339669" @default.
• W2917909827 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30565086" @default.
• W2917909827 hasPublicationYear "2018" @default.
• W2917909827 type Work @default.
• W2917909827 sameAs 2917909827 @default.
• W2917909827 citedByCount "14" @default.
• W2917909827 countsByYear W29179098272019 @default.
• W2917909827 countsByYear W29179098272020 @default.
• W2917909827 countsByYear W29179098272021 @default.
• W2917909827 countsByYear W29179098272022 @default.
• W2917909827 countsByYear W29179098272023 @default.
• W2917909827 crossrefType "journal-article" @default.
• W2917909827 hasAuthorship W2917909827A5011923508 @default.
• W2917909827 hasAuthorship W2917909827A5017439917 @default.
• W2917909827 hasAuthorship W2917909827A5026620381 @default.
• W2917909827 hasAuthorship W2917909827A5038937574 @default.
• W2917909827 hasAuthorship W2917909827A5054850662 @default.

• next